Journal
BRITISH JOURNAL OF PHARMACOLOGY
Volume 163, Issue 8, Pages 1565-1585Publisher
WILEY
DOI: 10.1111/j.1476-5381.2010.01160.x
Keywords
positron emission tomography (PET); radioisotope; drug development; radiopharmaceutical
Categories
Funding
- Cancer Research UK/Engineering and Physical Sciences Research Council/Medical Research Council/National Institute for Health Research [C2536/A10337]
- MRC [MC_U120081322] Funding Source: UKRI
- Cancer Research UK [10337] Funding Source: researchfish
- Medical Research Council [MC_U120081322] Funding Source: researchfish
Ask authors/readers for more resources
There is an increasing role for positron emission tomography (PET) in oncology, particularly as a component of early phase clinical trials. As a non-invasive functional imaging modality, PET can be used to assess both pharmacokinetics and pharmacodynamics of novel therapeutics by utilizing radiolabelled compounds. These studies can provide crucial information early in the drug development process that may influence the further development of novel therapeutics. PET imaging probes can also be used as early biomarkers of clinical response and to predict clinical outcome prior to the administration of therapeutic agents. We discuss the role of PET imaging particularly as applied to phase 0 studies and discuss the regulations involved in the development and synthesis of novel radioligands. The review also discusses currently available tracers and their role in the assessment of pharmacokinetics and pharmacodynamics as applied to oncology.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available